Literature DB >> 20443856

The emergence of extensively drug-resistant tuberculosis: a global health crisis requiring new interventions: part I: the origins and nature of the problem.

Jerrold J Ellner1.   

Abstract

Surveillance studies and outbreak investigations indicate that an extensively drug-resistant (XDR) form of tuberculosis (TB) is increasing in prevalence worldwide. In outbreak settings among HIV-infected, there is a high-case fatality rate. Better outcomes occur in HIV-uninfected, particularly if drug susceptibility test (DST) results are available rapidly to allow tailoring of drug therapy. This review will be presented in two segments. The first characterizes the problem posed by XDR-TB, addressing the epidemiology and evolution of XDR-TB and treatment outcomes. The second reviews technologic advances that may contribute to the solution, new diagnostics, and advances in understanding drug resistance and in the development of new drugs.

Entities:  

Mesh:

Year:  2008        PMID: 20443856      PMCID: PMC5350659          DOI: 10.1111/j.1752-8062.2008.00060.x

Source DB:  PubMed          Journal:  Clin Transl Sci        ISSN: 1752-8054            Impact factor:   4.689


  53 in total

1.  Low levels of drug resistance amidst rapidly increasing tuberculosis and human immunodeficiency virus co-epidemics in Botswana.

Authors:  T A Kenyon; M J Mwasekaga; R Huebner; D Rumisha; N Binkin; E Maganu
Journal:  Int J Tuberc Lung Dis       Date:  1999-01       Impact factor: 2.373

2.  XDR tuberculosis--implications for global public health.

Authors:  Mario C Raviglione; Ian M Smith
Journal:  N Engl J Med       Date:  2007-02-15       Impact factor: 91.245

3.  Development of streptomycin resistant strains of tubercle bacilli in pulmonary tuberculosis; results of simultaneous sensitivity tests in liquid and on solid media.

Authors:  D A MITCHISON
Journal:  Thorax       Date:  1950-06       Impact factor: 9.139

4.  Efficacy and safety of linezolid in multidrug resistant tuberculosis (MDR-TB)--a report of ten cases.

Authors:  Bent von der Lippe; Per Sandven; Oddbjørn Brubakk
Journal:  J Infect       Date:  2006-02       Impact factor: 6.072

5.  Nosocomial transmission of Mycobacterium bovis resistant to 11 drugs in people with advanced HIV-1 infection.

Authors:  A Guerrero; J Cobo; J Fortún; E Navas; C Quereda; A Asensio; J Cañón; J Blazquez; E Gómez-Mampaso
Journal:  Lancet       Date:  1997-12-13       Impact factor: 79.321

6.  Nosocomial transmission of multidrug-resistant Mycobacterium tuberculosis in Spain.

Authors:  J V Rullán; D Herrera; R Cano; V Moreno; P Godoy; E F Peiró; J Castell; C Ibañez; A Ortega; L S Agudo; F Pozo
Journal:  Emerg Infect Dis       Date:  1996 Apr-Jun       Impact factor: 6.883

7.  Comprehensive treatment of extensively drug-resistant tuberculosis.

Authors:  Carole D Mitnick; Sonya S Shin; Kwonjune J Seung; Michael L Rich; Sidney S Atwood; Jennifer J Furin; Garrett M Fitzmaurice; Felix A Alcantara Viru; Sasha C Appleton; Jaime N Bayona; Cesar A Bonilla; Katiuska Chalco; Sharon Choi; Molly F Franke; Hamish S F Fraser; Dalia Guerra; Rocio M Hurtado; Darius Jazayeri; Keith Joseph; Karim Llaro; Lorena Mestanza; Joia S Mukherjee; Maribel Muñoz; Eda Palacios; Epifanio Sanchez; Alexander Sloutsky; Mercedes C Becerra
Journal:  N Engl J Med       Date:  2008-08-07       Impact factor: 91.245

8.  Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis.

Authors:  Hye-Ryoun Kim; Seung Sik Hwang; Hyun Ji Kim; Sang Min Lee; Chul-Gyu Yoo; Young Whan Kim; Sung Koo Han; Young-Soo Shim; Jae-Joon Yim
Journal:  Clin Infect Dis       Date:  2007-10-15       Impact factor: 9.079

9.  The emergence of drug-resistant tuberculosis in New York City.

Authors:  T R Frieden; T Sterling; A Pablos-Mendez; J O Kilburn; G M Cauthen; S W Dooley
Journal:  N Engl J Med       Date:  1993-02-25       Impact factor: 91.245

10.  Spread of extensively drug-resistant tuberculosis.

Authors:  Sofia Samper; Carlos Martín
Journal:  Emerg Infect Dis       Date:  2007-04       Impact factor: 6.883

View more
  4 in total

1.  Aminoglycoside multiacetylating activity of the enhanced intracellular survival protein from Mycobacterium smegmatis and its inhibition.

Authors:  Wenjing Chen; Keith D Green; Oleg V Tsodikov; Sylvie Garneau-Tsodikova
Journal:  Biochemistry       Date:  2012-06-05       Impact factor: 3.162

2.  Redesign of substrate specificity and identification of the aminoglycoside binding residues of Eis from Mycobacterium tuberculosis.

Authors:  Benjamin C Jennings; Kristin J Labby; Keith D Green; Sylvie Garneau-Tsodikova
Journal:  Biochemistry       Date:  2013-07-16       Impact factor: 3.162

3.  Identification of Mycobacterial Ribosomal Proteins as Targets for CD4+ T Cells That Enhance Protective Immunity in Tuberculosis.

Authors:  Steven C Kennedy; Alison J Johnson; Sushma Bharrhan; Cecilia S Lindestam Arlehamn; Jiayong Xu; Scott J Garforth; John Chan; William R Jacobs; Alessandro Sette; Steven C Almo; Steven A Porcelli
Journal:  Infect Immun       Date:  2018-08-22       Impact factor: 3.441

Review 4.  Mycobacteriophages as Potential Therapeutic Agents against Drug-Resistant Tuberculosis.

Authors:  Anna Allué-Guardia; Rajagopalan Saranathan; John Chan; Jordi B Torrelles
Journal:  Int J Mol Sci       Date:  2021-01-13       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.